Stock Watch: The Sun Shines On AstraZeneca And GSK
But Seasonality And Minor Core Business Weaknesses Remain
Investors warmed to the results of both GSK and AstraZeneca, where pressures that had emerged for competitors earlier in first-quarter earnings season were not as impactful.
